Products
This classification denotes a combination drug for treatment of HIV. The first component, ABACAVIR, has US FDA Unique Ingredient Identifier of WR2TIP26VS. The second component, DOLUTEGRAVIR, has US FDA Unique Ingredient Identifier of DKO1W9H7M1. The third component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95.
How AGI delivers it
Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.
For Abacavir/dolutegravir/lamivudine, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.
Get the professional outcome delivered as software, priced on results, not headcount.
For Abacavir/dolutegravir/lamivudine, get the professional outcome delivered as software, priced on results, not headcount.
Value flow
Go deeper